Table 1 Baseline characteristics of included trials
First author, year of publication | Country | Type of surgery | Age range(yr) | Males(%) | Control group | No. randomized | No. in DEX group | No. in control group | ICU stay | DEX starting time | DEX dosage | Variables provided |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wu XH[[20]], 2016 | China | Non-cardiac Surgery | ≥ 65 | 57.9 | Placebo | 61 | 31 | 30 | Yes | Postoperative | 0.1 µg/kg/h, lasting 15 h | SEI, TST, AI, N1, N2, N3, REM |
Chen ZC[[13]], 2017 | China | Abdominal hysterectomy | 30–55 | NR | Placebo | 59 | 30 | 29 | No | PCA | Continuous dose: 0.05 µg/kg/h Bolus dose: 0.05 µg/kg | SEI, AI, N1, N2, N3, REM, Ramsay, VAS |
Jiang ZM[[18]], 2018 | China | Abdominal surgery | 60–70 | 58.8 | Placebo | 97 | Low dose group: 32 High dose group: 33 | 32 | No | PCA | Low dose group: 0.072 µg/kg/h continuous dose, 0.024 µg/kg bolus dose High dose group: 0.144 µg/kg/h continuous dose, 0.048 µg/kg bolus dose | SEI, AI, N1, N2, N3, REM, VAS |
Sun YM[[19]], 2022 | China | Non-cardiac surgery | ≥ 18 | 51.4 | Placebo | 68 | 33 | 35 | Yes | Postoperative | 0.1–0.2 µg/kg/h, lasting 72 h | SEI, TST, AI, N1, N2, N3, REM |
Wu Y[[14]], 2022 | China | Endoscopic sinus surgery | 18–65 | 55 | Placebo | 96 | 48 | 48 | No | Intraoperative | Loading dose: 0.5 µg/kg, continuous infusion: 0.2 µg/kg/h | SEI, AI, REM, Ramsay, VAS, PONV, POD |